Skip to main content

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

Completed · NCT02847728

Conditions: Melanoma, Lung Cancer

At a glance

Research payments reported, 2025
$10,420
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
1,189

About the trial

Sponsor
Bristol-Myers Squibb
Dates
Started 2016-07-28; completion 2024-03-31
Results posted
Not yet

This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US). The targeted countries in the EU for study participation include Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, and Spain. Study objectives are to assess the safety experience, survival, adverse event management, and outcomes of adverse events associated with nivolumab in routine oncology care facilities.

From ClinicalTrials.gov, last updated 2024-06-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $10,420 in research payments for this study in 2025 (6 payments).

Products named: Opdivo

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.